2,903 results match your criteria: "Small Cell Carcinoma of the Bladder"
Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.
Am J Clin Pathol
December 2024
Winship Cancer Institute of Emory University, Atlanta, GA, US.
Objectives: Urothelial carcinomas (UCs) encompass a heterogeneous group of tumors. Several histopathologic features are associated with poor clinical outcomes and limited treatment options. With new rising therapeutic modalities, we aimed to determine the pattern of expression of Trop-2 and ephrin B2 in UC with aggressive subtype histology and/or divergent differentiation (SH/DD).
View Article and Find Full Text PDFMalignant transformation of nephrogenic adenoma of the bladder: case report and literature review.
Transl Androl Urol
November 2024
Department of Urology, The Second Hospital of Dalian Medical University, Dalian, China.
Background: Nephrogenic adenoma (NA) is a rare benign tumor that can develop at any site of the urinary system, with the bladder being the most common, followed by the urethra, ureters, renal pelvises, etc. Currently, it is unclear what the pathogenesis of NA is. This study discussed a rare case of malignant transformation from NA to mesonephric adenocarcinoma of the bladder.
View Article and Find Full Text PDFA pan-cancer analysis of the oncogenic role of N-acetyltransferase 8 like in human cancer.
Discov Oncol
December 2024
Department of Urology, Yaan People's Hospital, Yaan, China.
Background: N-Acetyltransferase 8 Like (NAT8L) inhibits natural killer (NK)/T-cell cytotoxicity by impairing the formation of the immunological synapse via N-acetylaspartate (NAA). Existing research has predominantly focused on the metabolic functions of NAT8L, particularly in adipose tissues and myelination in the brain. However, in contrast to other N-acetyltransferases such as NAT1 and NAT2, the role of NAT8L in cancer has been less extensively studied.
View Article and Find Full Text PDFThe role of miR-152 in urological tumors: potential biomarkers and therapeutic targets.
Front Immunol
November 2024
Department of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China.
Article Synopsis
Hsa_circ_0088036 promotes tumorigenesis and chemotherapy resistance in hepatocellular carcinoma via the miR-140-3p/KIF2A axis.
Histol Histopathol
November 2024
Department of Pharmaceutical, Yan'an University Xianyang Hospital, Xianyang City, PR China.
Article Synopsis
Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database.
Prostate Cancer Prostatic Dis
November 2024
University of Colorado Cancer Center, Division of Medical Oncology, Department of Medicine, Aurora, CO, USA.
Article Synopsis
- Small cell prostate cancer (SCPC) is a rare, aggressive cancer with limited treatment guidelines, prompting this study to assess patient data and outcomes.
- The study analyzed 74 patients treated between 2010-2023, finding that most had metastatic disease and the primary treatment was platinum chemotherapy plus etoposide, with a median overall survival of 8.3 months for those with metastatic SCPC.
- Results showed that cisplatin plus etoposide improved survival over carboplatin plus etoposide, but there is no clear consensus on the best treatment, highlighting the need for further research in real-world clinical practices.
PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers.
Cell Rep Med
November 2024
Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address:
Small cell neuroendocrine cancers share biologic similarities across tissue types, including transient response to platinum-based chemotherapy with rapid progression of disease. We report a phase 1b study of pembrolizumab in combination with platinum-based chemotherapy in 15 patients with stage III-IV small cell bladder (cohort 1) or small cell/neuroendocrine prostate cancers (cohort 2). Overall response rate (ORR) is 43% with two-year overall survival (OS) rate of 86% (95% confidence interval [CI]: 0.
View Article and Find Full Text PDFHDAC1: a promising target for cancer treatment: insights from a thorough analysis of tumor functions.
Transl Cancer Res
October 2024
Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, Chongqing, China.
Article Synopsis
- Recent studies highlight the critical role of histone deacetylase 1 (HDAC1) in tumor development and prognosis, but previous research mainly focused on specific cancers rather than a comprehensive analysis across multiple cancer types.
- In this study, researchers investigated the oncogenic potential of HDAC1 across 33 different tumors using various databases and techniques, including immunohistochemistry and cell assays.
- Findings revealed that HDAC1 is highly expressed in many tumors, correlating with mRNA levels and patient prognosis, and also demonstrated that knockdown of HDAC1 in HCC cells significantly affected tumor cell behavior.
Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.
Sci Rep
November 2024
Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Article Synopsis
- Metastatic urothelial carcinoma (mUC) has a poor prognosis, and the study focuses on Prostaglandin Reductase 1 (PTGR1), which is crucial for the effectiveness of acylfulven drugs for treating specific mUC patients with ERCC2 mutations.
- The study evaluated PTGR1 expression in untreated mUC patients using immunohistochemistry (IHC), RNA expression analysis, and targeted genomic panels to identify candidates for clinical trials and assess the potential of PTGR1 as a prognostic biomarker.
- Results indicated that 40% of tumors tested positive for PTGR1 via IHC, demonstrating high sensitivity and specificity in RNA expression analysis, which correlated with tumor mutations and overall
Article Synopsis
- The JAVELIN Bladder 100 trial demonstrated that avelumab, used as a first-line maintenance therapy, improves overall survival and progression-free survival in patients with advanced urothelial carcinoma after platinum-based chemotherapy.
- The PATRIOT-II study analyzed real-world outcomes of avelumab in 160 patients across various healthcare centers, emphasizing survival, safety, and resource use over a median follow-up of 16 months.
- Findings indicated a median progression-free survival of 5.4 months and overall survival of 24.4 months, with some patients experiencing treatment-related adverse effects, supporting the continued use of avelumab in similar patient populations.
[Clinicopathological Features and Outcomes of Perioperative Treatment for Small Cell Carcinoma of the Bladder].
Sichuan Da Xue Xue Bao Yi Xue Ban
September 2024
（ 610041） Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.
Article Synopsis
Preclinical characterization of XB002, an anti-tissue factor antibody-drug conjugate for the treatment of solid tumors.
Mol Cancer Ther
November 2024
Iconic Therapeutics, South San Francisco, CA, United States.
Article Synopsis
Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer.
Bladder Cancer
October 2024
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Article Synopsis
Article Synopsis
- The urachus is a leftover structure from fetal development that connects the bladder to the belly button, and cancers arising from it, known as primary urachal carcinoma, are rare but aggressive.
- A case study presents a 48-year-old woman with abdominal pain and a mass, which was diagnosed as squamous cell carcinoma after imaging and biopsy.
- Treatment typically involves surgery to remove the tumor and surrounding tissue to reduce the chance of spreading, but guidelines are sparse due to the rarity of this type of cancer, with current protocols based on limited data.
Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder.
ESMO Open
November 2024
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address:
Article Synopsis
- The study examined the survival rates and pathologic responses of patients with cT1N0 small-cell neuroendocrine carcinoma (SCNEC) of the bladder who underwent neoadjuvant chemotherapy (neoCTX) from 1996 to 2023.
- Out of 30 patients, 70% received neoCTX, revealing that it significantly reduced the risk of disease progression and recurrence, and led to better disease-free survival (DFS) and overall survival (OS) rates.
- The findings suggest that neoCTX offers meaningful benefits for cT1 bladder SCNEC patients, including lower chances of worsening disease and improved outcomes compared to those with higher stage tumors.
The prognostic value and immunological role of calcium/calmodulin dependent protein kinase kinase 2 (CAMKK2) in pan-cancer study.
Medicine (Baltimore)
October 2024
Department of Emergency Medicine, Emergency and Critical Care Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Article Synopsis
- There is currently no comprehensive assessment of calcium/calmodulin dependent protein kinase kinase 2 (CAMKK2) across various cancers, prompting this study to integrate multi-omics and clinical data.
- The research found high mutation rates of CAMKK2 in uterine corpus endometrial carcinoma and elevated expression levels in prostate adenocarcinoma, with its expression impacting survival outcomes in multiple cancer types.
- CAMKK2 may serve as a promising biomarker for prognosis and predicting immunotherapy effectiveness, particularly noted in kidney renal clear cell carcinoma where higher expression correlates with improved survival.
Surgical treatment of urachal adenocarcinoma with lung metastasis: A case report and literature review.
Thorac Cancer
December 2024
Department of Thoracic Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Article Synopsis
- * Most urachal cancers are classified as intestinal adenocarcinomas (90%), and they often occur in the lower urachal tube or bladder dome, leading to late diagnoses due to the silent nature of early stages.
- * Treatment options for this aggressive cancer include surgery and chemotherapy (like cisplatin), with some patients showing positive responses to targeted therapies; a case study highlighted successful surgical treatment for a patient with advanced disease.
Treatment and survival of non-metastatic small cell carcinoma of the bladder from multiple centers in China.
Sci Rep
October 2024
Department of Radiation Oncology, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 113 Baohe Avenue, Longgang District, Shenzhen, 518172, Guangdong, China.
Article Synopsis
- Small cell carcinoma of the bladder (SCCB) is a rare and aggressive tumor, and this study analyzed its characteristics and treatment outcomes among patients in China from 2007 to 2022.
- In the study, 20 patients were evaluated, with half having localized disease and half with locally advanced disease, and most received chemotherapy as part of their treatment.
- The findings showed that those who underwent radical treatments had significantly better overall survival (OS) and progression-free survival (PFS) rates compared to those who received local treatments, emphasizing the importance of chemotherapy in managing this aggressive cancer.
USP5 promotes tumor progression by stabilizing SLUG in bladder cancer.
Oncol Lett
December 2024
Department of Radiotherapy, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, P.R. China.
Article Synopsis
- - Bladder cancer is the second most common urological cancer worldwide, and the study focuses on the role of ubiquitin-specific proteinase 5 (USP5) in the cancer's aggressive progression and prognosis, using data from The Cancer Genome Atlas. - High levels of USP5 are linked to shorter survival and higher disease stages in bladder cancer patients, with experiments showing that overexpression of USP5 in T24 cells led to increased cell proliferation, invasion, and expression of epithelial-mesenchymal transition markers, while knockdown of USP5 had the opposite effects. - The study also found that USP5 interacts with SLUG, a protein that may play a role in promoting cancer cell characteristics, indicating a complex mechanism by which USP5 contributes to
A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder.
Clin Genitourin Cancer
December 2024
Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Electronic address:
Article Synopsis
- Neuroendocrine carcinoma of the bladder (NEC-bladder) is a rare and aggressive cancer, and the study focused on patients treated between 2001-2021 to assess treatment outcomes.
- The research found that most patients received neoadjuvant chemotherapy (NAC), and higher rates of pathologic complete response (pCR) and downstaging were associated with improved progression-free and overall survival (PFS and OS).
- Key findings indicated that achieving ypN0 status (negative nodes post-treatment) correlated with better long-term survival, while the presence of nodal involvement (pN+) was linked to poorer outcomes.
Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.
JCO Precis Oncol
October 2024
Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Article Synopsis
Expression of POU2F3 Transcription Factor and POU2AF2, POU2F3 Coactivator, in Tuft Cell-like Carcinoma and Other Tumors.
Am J Surg Pathol
January 2025
Laboratory of Pathology, National Cancer Institute, Bethesda, MD.
Article Synopsis
- Epithelial chemosensory cells, called tuft cells, are linked to tumor formation, especially in lung cancers, related to the POU2F3 transcription factor which indicates tuft cell lineage.
- A study analyzed POU2F3 expression in over 8,000 tumor samples, finding positive expression in roughly 12.4% of epithelial tumors and 4.6% of mesenchymal/neuroectodermal tumors, with most neuroendocrine tumors showing strong POU2F3 presence.
- Co-expression of POU2F3 with coactivators like POU2AF2 gives a more specific tumor marker, suggesting that while POU2F3 is sensitive for tuft cell differentiation
Prediction of immunotherapy response using mutations to cancer protein assemblies.
Sci Adv
September 2024
Department of Medicine and Moores Cancer Center, School of Medicine, University of California San Diego, San Diego, CA, USA.
Article Synopsis
- Immune checkpoint inhibitors have transformed cancer treatment, but many patients still do not respond well to therapy.
- The study shows that by analyzing tumor mutation burden (TMB) alongside specific protein assemblies, researchers can predict immunotherapy responses in bladder and non-small cell lung cancers, identifying 13 crucial protein assemblies related to treatment outcomes.
- These findings not only improve the ability to distinguish between patients who will respond and those who won’t, but they also highlight important genes influencing response, providing a valuable guide for future cancer treatment strategies.
Unusual coexistence: A case of mixed small and large cell neuroendocrine tumor in a bladder previously affected by bilharzial cystitis.
Clin Case Rep
September 2024
University of the Witwatersrand, Department of Surgery, Division of Urology Klerksdorp hospital Klerksdorp Northwest South Africa.
Article Synopsis
- * A case is reported involving a 64-year-old man with mixed large and small cell neuroendocrine tumors of the bladder, diagnosed after a radical cystectomy and supported by specific immunohistochemical staining.
- * The case is significant because it is the first documented occurrence of mixed neuroendocrine carcinoma connected to bilharzial cystitis, suggesting the need for more research on their relationship and similar patterns in other organs.